NCT01795677 is a Phase 2 clinical trial of Ruxolotinib in Myelofibrosis, sponsored by French Innovative Leukemia Organisation.

Who is sponsoring NCT01795677?

NCT01795677 is sponsored by French Innovative Leukemia Organisation.

What drugs are being tested in NCT01795677?

Interventions in NCT01795677: Ruxolotinib.

What condition does NCT01795677 study?

NCT01795677 studies Myelofibrosis.

Is NCT01795677 still recruiting?

NCT01795677 is currently completed. Last updated 26 July 2022.

Last reviewed 2022-07-26 · How we verify

NCT01795677

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

JAK2 Inhibitors RUXOLITINIB in Patients With High or Intermediate Risk Primary or Secondary Myelofibrosis Eligible for Allogeneic Stem Cell Transplantation: a Prospective Multicentric Phase II Study

Completed Phase 2 Last updated 26 July 2022

What this trial tests

Phase 2 trial testing Ruxolotinib in Myelofibrosis in 78 participants. Completed in 1 March 2019.

Timeline

1 December 2012

Primary endpoint
1 May 2018

1 March 2019

Quick facts

Lead sponsor	French Innovative Leukemia Organisation
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	1 December 2012
Primary completion	1 May 2018
Estimated completion	1 March 2019
Sites	1 location across France

Drugs / interventions tested

Ruxolotinib — full drug profile →

Conditions studied

Myelofibrosis — all drugs for Myelofibrosis →

Sponsor

French Innovative Leukemia Organisation — full company profile →

Who can join

Adults 18 to 69, any sex, with Myelofibrosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

DFS
Time frame: 24 months after inclusion
DFS is defined as the probability to be alive and in remission

Sponsor's own description

JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with primary or secondary myelofibrosis : a prospective phase II

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication.
Loh CY, Arya A, Naema AF, Wong WF, et al · · 2019 · cited 241× · PMID 30847297 · DOI 10.3389/fonc.2019.00048
Case report: Central nervous system involvement of human graft versus host disease: Report of 7 cases and a review of literature.
Ruggiu M, Cuccuini W, Mokhtari K, Meignin V, et al · · 2017 · cited 46× · PMID 29049232 · DOI 10.1097/md.0000000000008303
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, et al · · 2019 · cited 28× · PMID 31920387 · DOI 10.2147/cmar.s212559
Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups.
Robin M, Porcher R, Orvain C, Bay JO, et al · · 2021 · cited 25× · PMID 33767402 · DOI 10.1038/s41409-021-01252-7
Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis.
Matsubara E, Yamanouchi J, Kitazawa R, Azuma T, et al · · 2016 · cited 7× · PMID 27840748 · DOI 10.1155/2016/8751329
Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant.
Byrne M, Savani B, Savona MR. · · 2018 · cited 5× · PMID 30210754 · DOI 10.1177/2040620718786437
Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
Yacoub A, Odenike O, Verstovsek S. · · 2014 · cited 5× · PMID 25145552 · DOI 10.1007/s11899-014-0229-y
Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis.
Villar S, Curis E, Schlageter MH, Bosselut N, et al · · 2025 · cited 1× · PMID 40274649 · DOI 10.1007/s00262-025-04046-8

Verify or expand the search:

Other recruiting trials for Myelofibrosis

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06781099 — Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis · NA · recruiting
NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
NCT07342712 — Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels · active not recruiting
NCT06533813 — Clinical Epidemiology in Contemporary Patients With Myelofibrosis. · recruiting

Other French Innovative Leukemia Organisation trials

Trials by the same sponsor.

NCT07007052 — Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Bl · Phase 2 · not yet recruiting
NCT06547866 — Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated f · Phase 2 · not yet recruiting
NCT06377579 — OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia · recruiting
NCT06263387 — Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible · recruiting
NCT06186648 — Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter S · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01795677 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by French Innovative Leukemia Organisation
Last refreshed: 26 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01795677.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing